is an academic article analyzing the results of recent clinical trials for the Alzheimer drug aducanumab (ADU). It was published by Alzheimer’s & Dementia, the Journal of the Alzheimer’s Association on November 1st, 2020. It was authored by David S. Knopman, David T. Jones, and Michael D. Greicius. It argues that there is currently insufficient evidence in support of its use [Ix4], and that a new phase III trial is required.
In sum. In sum, the data from the EMERGE and ENGAGE trials, as presented by Biogen to date, do not support the conclusion that ADU has clinical benefits. Further study is needed.